Table 5. Adverse Events related to Nervous System.
SD – Singel Dose, OD - Once Daily, BID - Twice Daily
| Study | Somnolence, n (%) | Anxiety, n (%) | Dizziness, n (%) | Headache, n (%) |
|---|---|---|---|---|
| Ankrom et al.9 | ||||
| 60 mg OD | 1 (3.8) | - | - | 1 (3.8) |
| Goadsby et al.10 | ||||
| 10 mg OD | 2 (2) | - | - | - |
| 30 mg OD | 2 (1) | - | - | - |
| 60 mg OD | 6 (3) | - | - | - |
| 30 mg BID | 1 (1) | - | - | - |
| 60 mg BID | 0 | - | - | - |
| Placebo | 2 (1) | - | - | - |
| Min et al.11 | ||||
| 170 mg | - | - | 5 (21.7) | 7 (30.4) |
| Placebo | - | - | 1 (9.1) | 3 (27.3) |
| Boinpally et al.12 | ||||
| 300 mg SD | 0 | - | 0 | 0 |
| Placebo | 0 | - | 0 | 0 |
| Ailani et al.13 | ||||
| 10 mg OD | 7 (3.2) | 2 (0.9) | - | - |
| 30 mg OD | 4 (1.8) | 1 (0.4) | - | - |
| 60 mg OD | 4 (1.7) | 5 (2.2) | - | - |
| Placebo | 2 (0.9) | 2 (0.9) | - | - |
| Klein et al.16 | ||||
| 60 mg OD | 14 (2.0) | 14 (2.0) | 17 (2.5) | - |
| Ashina et al.17 | ||||
| 60 mg OD | - | 16 (2.9) | 17 (3.1) | - |